Skip to Content
Merck
  • Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels.

Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels.

Biomaterials (2014-08-27)
Angela L Zachman, Xintong Wang, Jason M Tucker-Schwartz, Sean T Fitzpatrick, Sue H Lee, Scott A Guelcher, Melissa C Skala, Hak-Joon Sung
ABSTRACT

Peripheral artery disease (PAD) is characterized by vessel occlusion and ischemia in the limbs. Treatment for PAD with surgical interventions has been showing limited success. Moreover, recent clinical trials with treatment of angiogenic growth factors proved ineffective as increased angiogenesis triggered severe inflammation in a proportionally coupled fashion. Hence, the overarching goal of this research was to address this issue by developing a biomaterial system that enables controlled, dual delivery of pro-angiogenic C16 and anti-inflammatory Ac-SDKP peptides in a minimally-invasive way. To achieve the goal, a peptide-loaded injectable microgel system was developed and tested in a mouse model of PAD. When delivered through multiple, low volume injections, the combination of C16 and Ac-SDKP peptides promoted angiogenesis, muscle regeneration, and perfusion recovery, while minimizing detrimental inflammation. Additionally, this peptide combination regulated inflammatory TNF-α pathways independently of MMP-9 mediated pathways of angiogenesis in vitro, suggesting a potential mechanism by which angiogenic and inflammatory responses can be uncoupled in the context of PAD. This study demonstrates a translatable potential of the dual peptide-loaded injectable microgel system for PAD treatment.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Ethyl hexanoate, ≥99%
Sigma-Aldrich
Tetrahydrofuran, anhydrous, contains 250 ppm BHT as inhibitor, ≥99.9%
Sigma-Aldrich
Diethyl azodicarboxylate solution, purum, ~40% in toluene (H-NMR)
Supelco
Tetrahydrofuran, Selectophore, ≥99.5%
Sigma-Aldrich
Diethyl ether, contains 1 ppm BHT as inhibitor, anhydrous, ≥99.7%
Supelco
Tetrahydrofuran, HPLC grade, ≥99.9%, inhibitor-free
Sigma-Aldrich
Tetrahydrofuran, anhydrous, ≥99.9%, inhibitor-free
Sigma-Aldrich
Diethyl ether
Sigma-Aldrich
Ethyl hexanoate, natural, ≥98%, FCC, FG
Sigma-Aldrich
Ethyl hexanoate, ≥98%, FCC, FG
Supelco
Tetrahydrofuran, analytical standard
Supelco
Tetrahydrofuran, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Diethyl ether, analytical standard
Sigma-Aldrich
Diethyl ether, ACS reagent, ≥98.0%, contains ≤2% ethanol and ≤10ppm BHT as inhibitor
Supelco
Residual Solvent - Toluene, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Diethyl ether, suitable for HPLC, ≥99.9%, inhibitor-free
Sigma-Aldrich
Tetrahydrofuran, inhibitor-free, suitable for HPLC, ≥99.9%
Supelco
Ethyl hexanoate, analytical standard
Sigma-Aldrich
Diethyl ether, reagent grade, ≥98%, contains ≤2% ethanol and ≤10ppm BHT as inhibitor
Sigma-Aldrich
Tetrahydrofuran, contains 200-400 ppm BHT as inhibitor, ACS reagent, ≥99.0%
Sigma-Aldrich
Diethyl ether, ACS reagent, anhydrous, ≥99.0%, contains BHT as inhibitor
Sigma-Aldrich
Tetrahydrofuran, ACS reagent, ≥99.0%, contains 200-400 ppm BHT as inhibitor
Sigma-Aldrich
Diethyl ether, anhydrous, ACS reagent, ≥99.0%, contains BHT as inhibitor
Sigma-Aldrich
Toluene, ACS reagent, ≥99.5%
Sigma-Aldrich
Dichloromethane, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
Toluene, ACS reagent, ≥99.5%
Sigma-Aldrich
Dichloromethane, contains 40-150 ppm amylene as stabilizer, ACS reagent, ≥99.5%
Sigma-Aldrich
Toluene, ACS reagent, ≥99.5%
Sigma-Aldrich
Dichloromethane, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
Dichloromethane, biotech. grade, 99.9%, contains 40-150 ppm amylene as stabilizer